Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide, as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
$1M to $10M
Last funding date
Company LinkedInVisit Profile ⤴
Company Email Address
Contact Phone Number
+32 16 75 13 10
"Using CyberLeads, we closed a $54,000/year client. That's 35,600% ROI."
Andrew Miller - Co-Founder & CEO WordSmiths, Inc
Booked calls in your calendar with companies that just raised millions and are looking to outsource.